Metsera Inc. (NASDAQ:MTSR - Get Free Report)'s share price gapped up prior to trading on Monday . The stock had previously closed at $29.38, but opened at $31.34. Metsera shares last traded at $28.95, with a volume of 265,955 shares trading hands.
Wall Street Analysts Forecast Growth
A number of research analysts recently commented on the stock. Guggenheim raised their price objective on shares of Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research note on Tuesday, June 10th. Bank of America started coverage on Metsera in a research note on Tuesday, February 25th. They set a "buy" rating and a $38.00 price target for the company. Cantor Fitzgerald began coverage on Metsera in a research report on Tuesday, February 25th. They set an "overweight" rating on the stock. Finally, Evercore ISI began coverage on Metsera in a report on Tuesday, February 25th. They issued an "outperform" rating for the company.
Check Out Our Latest Analysis on MTSR
Metsera Trading Down 5.5%
The company's 50-day moving average price is $24.84.
Metsera (NASDAQ:MTSR - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($1.03) EPS for the quarter.
Institutional Investors Weigh In On Metsera
Several large investors have recently modified their holdings of MTSR. Strs Ohio acquired a new stake in shares of Metsera during the first quarter worth $76,000. New York State Common Retirement Fund purchased a new position in Metsera in the 1st quarter worth about $131,000. Corebridge Financial Inc. acquired a new stake in Metsera during the 1st quarter worth about $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Metsera during the 1st quarter worth about $248,000. Finally, MetLife Investment Management LLC purchased a new stake in Metsera during the first quarter valued at about $254,000.
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Recommended Stories
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
